Daraxonrasib
-
{
- All
- News
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
-
Pancreatic Cancer Breakthrough: New Daily Pill Doubles Survival Time For Advanced Patients
A new once-daily targeted therapy, daraxonrasib, has nearly doubled survival in patients with advanced pancreatic cancer in a landmark Phase 3 trial. Experts are calling it one of the most significant breakthroughs against one of the world's deadliest cancers in decades.
-
Experimental Pill Promises New Hope For Deadly Pancreatic Cancer
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
-
Pancreatic Cancer Breakthrough: New Daily Pill Doubles Survival Time For Advanced Patients
A new once-daily targeted therapy, daraxonrasib, has nearly doubled survival in patients with advanced pancreatic cancer in a landmark Phase 3 trial. Experts are calling it one of the most significant breakthroughs against one of the world's deadliest cancers in decades.
-
Experimental Pill Promises New Hope For Deadly Pancreatic Cancer
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
